Israel is at the vanguard of a new psychedelic revolution
Wired, December 18, 2023
More than 50 years after the psychedelic revolution, Israeli startups are proving to be pioneers in the use of mind-altering drugs—from mushrooms to medical-grade cannabis—to treat conditions like depression and PTSD.
Health Benefits Provider Will Cover Psilocybin-Assisted Therapy In States Where It’s Legal
Marijuana Movement, December 15, 2023
A Massachusetts company that bills itself as “the first and only licensed provider of psychedelic health plans” announced on Tuesday that it will cover psilocybin-assisted therapy in states where it’s legal.
MDMA-Assisted Therapy for PTSD Edges Toward Acceptance – When Might It Be Approved?
Psychedelic Spotlight, December 13, 2023
If approved, MDMA-AT would be the first psychedelic-assisted therapy procedure for PTSD.
FDA to review MDMA-assisted therapy, a milestone for psychedelics
The Washington Post, December 12, 2023
MAPS Public Benefit Corp. filed an application on Tuesday with the U.S. Food and Drug Administration to approve MDMA in combination with therapy to treat post-traumatic stress disorder, in what would be the first treatment of its kind.
Shroom For Diversity
Herald Sun, December 5, 2023
Australia’s psilocybin population contains greater genetic diversity than the world’s commercially available mushrooms, Australian researchers say.
The real risks of psychedelics, explained by an expert
Big Think, December 3, 2023
The real risks of psychedelics, explained by Johns Hopkins professor Dr. Matthew Johnson.
Harvard Announces Study of Psychedelics in Society and Culture Following $16M Donation
The Harvard Crimson, October 26, 2023
Harvard will be launching a new interdisciplinary program focusing on psychedelic drugs, the University announced last week.
Funded by a $16 million donation from the Gracias Family Foundation, the Study of Psychedelics in Society and Culture will fund “cutting-edge scholarship” and “research support,” along with endowing a professorship in the field, according to the Harvard Gazette, a University-run publication.
First Licence for Psilocybe Cultivation in NZ
NZ Doctor, October 26, 2023
The granting of a licence to cultivate indigenous fungi containing psilocybin, is the first of its kind in New Zealand and a major milestone in a Māori health science collaboration.
Roland Griffiths Is Dead at 77; Led a Renaissance in Psychedelics Research
New York Times, October 17, 2023
Roland Griffiths, a professor of behavioral science and psychiatry whose pioneering work in the study of psychedelics helped usher in a new era of research into those once banned substances — and reintroduced the mystical into scientific discourse about them — died on Monday at his home in Baltimore.
Psychedelics Seem to Change How Fast Our Brains Learn — Researchers Might Finally Understand How
The Conversation, October 16, 2023
Psychedelics Seem to Change How Fast Our Brains Learn
Survey Shows ‘Striking Positive Shift in Attitudes’ Toward Psychedelics Among Psychiatrists
High Times, October 3, 2023
Psychiatrists in the United States are increasingly receptive to psychedelic therapy, according to a newly released survey.
Psychedelic drug market set to reach $7.2 billion in 2029, forecasts GlobalData
Globaldata, September 25, 2023
The psychedelic drug market is on the brink of extraordinary growth, projected to soar to $7.2 billion by 2029, reflecting a robust 55% compound annual growth rate (CAGR).
Should psychedelics be used for therapy? Psychiatrists think so
Fox8, September 22, 2023
In 2016, only about 43% of doctors agreed that psychedelics such as LSD, Psilocybin and other similar medicines could help with psychiatric disorders. But just seven years later, more than 80% of those surveyed feel that the medical use of these medicines could help.
Success of MDMA in PTSD Study Could Pave the Way for U.S. Approval of the Psychedelic
Time, September 15, 2023
“It’s the first innovation in PTSD treatment in more than two decades. And it’s significant because I think it will also open up other innovation,” said Amy Emerson, CEO of MAPS Public Benefit Corporation, the research sponsor.
The firms hoping to take psychedelic drugs mainstream
BBC, September 15, 2023
This July in Bend, Oregon, Josh Goldstein facilitated one of the first psilocybin sessions under the state’s new regulatory framework for people to access psilocybin.
MDMA Therapy Inches Closer to Approval
New York Times, September 14, 2023
Results of a new study may offer regulators enough evidence to allow MDMA to be considered for use as a PTSD treatment.
Could psychedelic trips inspire faster climate action?
Raconteur, September 5, 2023
A growing body of research suggests that psychedelic experiences could improve our connectedness to nature and inspire faster action on the climate crisis.
Magic mushrooms could treat depression, anxiety and PTSD, researchers claim
NY Post, September 1, 2023
The Journal of the American Medical Association published an investigation into the use of psilocybin mushrooms to treat major depressive disorder (MDD). In some cases, MDD doesn’t respond to such treatments as medication or psychotherapy. But a growing body of evidence suggests that psilocybin, the active ingredient in “magic” mushrooms, can help with depression and other conditions, such as anxiety and post-traumatic stress disorder.
How taking MDMA with your partner could boost your relationship
Financial Review, August 18, 2023
An Australian team hopes to become the first researchers to measure the outcome of using MDMA to help couples in conflict.
MDMA and magic mushrooms have arrived: psychedelic trip to new therapies
Herald Sun, July 24, 2023
MDMA and psilocybin can now be used clinically in Australia. Here’s a look at what that means, how we came to this point and the ASX stocks involved.